InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.059

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Doherty Clinical Trials to host HERACLES trial 12 Mar 2025 10:10AM $0.072 $0.059 fallen by 18.06%
$18 Appendix 4D and FY2025 Half Year Financial Report 25 Feb 2025 1:38PM $0.091 $0.059 fallen by 35.16%
$18 SOF-SKN passes required in vitro safety tests 4 Feb 2025 8:17AM $0.085 $0.059 fallen by 30.59%
$18 December 2024 Quarterly Activities Report and Appendix 4C 29 Jan 2025 8:17AM $0.100 $0.059 fallen by 41%
$18 Notice under s708A(12C)(e) of the Corporations Act 2001 10 Jan 2025 4:29PM $0.083 $0.059 fallen by 28.92%
$18 Notification regarding unquoted securities - NOX 10 Jan 2025 4:25PM $0.083 $0.059 fallen by 28.92%
$18 Notification regarding unquoted securities - NOX 10 Jan 2025 4:22PM $0.083 $0.059 fallen by 28.92%
$18 Convertible Note update 18 Dec 2024 3:01PM $0.094 $0.059 fallen by 37.23%
$18 Change of Director's Interest Notice - BP 16 Dec 2024 8:33AM $0.100 $0.059 fallen by 41%
$18 Notification of cessation of securities - NOX 16 Dec 2024 8:22AM $0.100 $0.059 fallen by 41%
$18 Contract Research Organisation signed for HERACLES trial 4 Dec 2024 9:31AM $0.100 $0.059 fallen by 41%
$18 Results of Meeting 19 Nov 2024 3:25PM $0.105 $0.059 fallen by 43.81%
$18 Noxopharm 2024 AGM Corporate Presentation 19 Nov 2024 8:29AM $0.110 $0.059 fallen by 46.36%
$18 Noxopharm 2024 AGM Chair Address 19 Nov 2024 8:27AM $0.110 $0.059 fallen by 46.36%
$18 Noxopharm enhances 2024 cash position via R&D rebate 12 Nov 2024 8:13AM $0.105 $0.059 fallen by 43.81%
$18 Notification of cessation of securities - NOX 6 Nov 2024 4:23PM $0.110 $0.059 fallen by 46.36%
$18 Proposed issue of securities - NOX 5 Nov 2024 8:45AM $0.130 $0.059 fallen by 54.62%
$18 Additional convertible note for long-term shareholder 5 Nov 2024 8:20AM $0.130 $0.059 fallen by 54.62%
$18 September 2024 Quarterly Activities report and Appendix 4C 29 Oct 2024 8:10AM $0.130 $0.059 fallen by 54.62%
$18 2024 AGM Addendum to the Notice of Meeting and Proxy 25 Oct 2024 8:21AM $0.130 $0.059 fallen by 54.62%
$18 Minor correction to funding announcement 14 Oct 2024 8:30AM $0.110 $0.059 fallen by 46.36%
$18 AGM Letter of Access, Notice of Meeting and Proxy 14 Oct 2024 8:24AM $0.110 $0.059 fallen by 46.36%
$18 Unlisted Options Upcoming Expiry 11 Oct 2024 7:39AM $0.105 $0.059 fallen by 43.81%
$18 SOF-SKN manufacturer signed for HERACLES clinical trial 10 Oct 2024 8:26AM $0.115 $0.059 fallen by 48.70%
$18 Annual Report to shareholders 30 Sep 2024 11:39AM $0.105 $0.059 fallen by 43.81%

76 - 100 of 800 results

Page 4 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.